Zoetis Inc. — Q1 2021 Form 10-Q Summary
Business context and reporting period
Zoetis is a global animal-health company selling medicines, vaccines, diagnostics and related products across companion-animal and livestock markets. This unaudited report covers the three months ended March 31, 2021, compared with the same period in 2020. The interim financial statements were reviewed by KPMG, not audited.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 / prior balance |
|---|---|---|
| Revenue | $1.871 billion | $1.534 billion; up 22% reported and 21% operationally |
| Income before tax | $687 million | $497 million |
| Net income attributable to Zoetis | $559 million | $423 million; up 32% |
| Diluted EPS | $1.17 | $0.88 |
| Adjusted net income / diluted EPS (non-GAAP) | $603 million / $1.26 | $455 million / $0.95 |
| Cash from operations | $400 million | $408 million |
| Capital expenditures | $77 million | $94 million |
| Cash and cash equivalents | $3.602 billion | $3.604 billion at December 31, 2020 |
| Debt | $7.25 billion principal; $7.187 billion current and long-term debt carrying amounts combined | $7.25 billion principal at December 31, 2020 |
| Working capital / current ratio | $4.728 billion / 3.29:1 | $4.441 billion / 3.05:1 at December 31, 2020 |
Cost of sales was 29.3% of revenue, implying a 70.7% consolidated gross margin, versus 29.9% cost of sales and a 70.1% gross margin in Q1 2020. Net margin was approximately 29.9%, compared with 27.6%. Operating cash flow less capital expenditures was approximately $323 million, versus $314 million.
Material changes and drivers
- Companion-animal revenue rose 35% to $1.076 billion; livestock revenue rose 9% to $779 million. Growth was driven by parasiticides, dermatology, diagnostics and new products, including Simparica Trio.
- U.S. revenue increased 19% to $933 million, with companion-animal growth more than offsetting lower livestock sales. International revenue increased 27% to $922 million, including 25% operational growth and a 2% foreign-exchange benefit.
- Revenue growth reflected approximately 16% volume growth from in-line products and 5% from new products. Foreign exchange added about 1 percentage point to reported growth.
- Cost of sales increased 20%, slower than revenue growth; management cited favorable product mix, partly offset by foreign exchange and higher freight costs. SG&A rose 5% and R&D rose 10%, while both declined as a share of revenue.
- The effective tax rate increased to 18.8% from 14.9%, primarily reflecting differences in discrete tax benefits and the mix of earnings by jurisdiction. Interest expense increased 8%, mainly following the May 2020 debt issuance. Q1 2020 other income included a $17 million gain related to the sale of U.S. manufacturing sites.
- Operating cash flow declined $8 million, with timing of receipts and payments partly offset by higher cash earnings. Zoetis repurchased approximately 1.16 million shares under its authorization and paid $119 million in dividends; quarterly dividends declared were $0.25 per share, up from $0.20.
Outlook, risks and unusual items
- The supplied filing text refers to 2021 financial guidance but does not provide clear guidance values. Management said the effects of COVID-19 remained uncertain and could affect customer demand, staffing, supply chains, manufacturing, R&D timelines and financial results.
- Zoetis remained operational as an essential business, but described potential disruption from the pandemic, including a short-lived disruption to certain product components after the U.S. government invoked the Defense Production Act. Management noted possible future borrowing, additional interest costs, or cash-preservation actions such as reducing dividends or delaying capital spending.
- Other stated risks include product safety or quality issues, competition and generic entry, R&D and launch delays, animal disease outbreaks, foreign-exchange movements, regulatory and tax changes, customer consolidation, manufacturing interruptions, cybersecurity threats and litigation.
- The company reported $192 million of net uncertain-tax-position liabilities, excluding $15 million of related interest and penalties. It did not expect a significant reduction in uncertain tax positions within the next 12 months.
- Legal matters include environmental proceedings in Brazil and a pending appeal in the Michigan feed-contamination litigation; management could not estimate reasonably possible losses above accruals. The Belgium excess-profit tax matter remained unresolved. The Alpharma European Commission proceedings concluded in March 2021; the fine had already been paid and Pfizer had reimbursed Zoetis.
- Management stated that it believed available cash, operating cash flows and financing arrangements would support future cash needs, while cautioning that economic conditions could affect liquidity or access to financing. The company was compliant with credit-facility covenants and had no revolving-facility or commercial-paper borrowings outstanding.
Important facts for investors to verify
- Consult the complete filing and subsequent disclosures for the specific 2021 guidance figures, which are not clear in the supplied text.
- Assess whether Q1 companion-animal growth and product-launch momentum are sustainable, and monitor the livestock recovery and COVID-19 effects on customers and supply.
- Track cash conversion, working-capital movements, share repurchases, dividends and the scheduled $600 million of 2021 debt maturities.
- Review the non-GAAP adjusted earnings reconciliation alongside GAAP results; adjusted measures exclude purchase-accounting, acquisition-related and certain significant items.
- Monitor tax exposures, pending litigation and evolving pandemic, foreign-exchange, regulatory and supply-chain risks.